Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adalimumab for High-Risk Hidradenitis Suppurativa Progression
2025-522505-37-00Phase 4Authorised
- Sponsor
- Gentofte Hospital
- Start
- Aug 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in hidradenitis suppurativa (HS) comparing Adalimumab arm with Standard of care arm (2 arms). Primary endpoint: Development of severe hidradenitis suppurativa over 2 years. Planned start Aug 2026; status: authorised.
02
Drugs
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on 2025-522505-37-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-522505-37-00.